While TGF-β pathway mutation is not associated with RFS in CRC patients treated with adjuvant FOLFOX/XELOX chemotherapy, it may be fatal in CRC patients who have recurred after curative surgery. The gene discussed is TGFB1; the disease is colorectal carcinoma.